Skip to content

HEALTH DISCOVERY CORPORATION: 10-K/A filed 2020-05-14

What HEALTH DISCOVERY CORPORATION reported in its annual report amendment filed 2020-05-14 (fiscal FY 2019): 30 published measures, 210 facts as tagged in accession 0001104659-20-061520.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-K/A (annual report amendment)
Filed
2020-05-14
Fiscal period
fiscal FY 2019
Accession
0001104659-20-061520 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All HEALTH DISCOVERY CORPORATION filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-12-312,312,516USD
At 2019-09-302,540,992USD
At 2019-06-302,720,566USD
At 2019-03-31114,509USD
At 2018-12-31152,975USD
At 2018-09-30223,127USD
At 2018-06-30305,925USD
At 2018-03-31446,713USD
At 2017-12-31459,170USD
At 2016-12-31873,971USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-12-312,783,023USD
At 2019-09-301,310,565USD
At 2019-06-301,253,744USD
At 2019-03-311,281,829USD
At 2018-12-311,146,723USD
At 2018-09-301,026,355USD
At 2018-06-30937,837USD
At 2018-03-31899,538USD
At 2017-12-31744,460USD
At 2016-12-31351,313USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-12-31-470,507USD
At 2019-09-301,230,427USD
At 2019-06-301,466,822USD
At 2019-03-31-1,167,320USD
At 2018-12-31-993,748USD
At 2018-09-30-803,228USD
At 2018-06-30-631,912USD
At 2018-03-31-452,825USD
At 2017-12-31-285,290USD
At 2016-12-31522,658USD
At 2015-12-31768,668USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-12-312,295,720USD
At 2019-09-302,523,707USD
At 2019-06-302,681,669USD
At 2019-03-3127,282USD
At 2018-12-3167USD
At 2018-09-304,539USD
At 2018-06-3021,658USD
At 2018-03-3196,766USD
At 2017-12-3143,543USD
At 2016-12-3141,251USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-01-01 to 2019-12-311,560,706USD365
2019-07-01 to 2019-09-30-236,395USD92
2019-04-01 to 2019-06-302,124,498USD91
2019-01-01 to 2019-03-31-176,879USD90
2018-01-01 to 2018-12-31-795,474USD365
2018-07-01 to 2018-09-30-202,656USD92
2018-04-01 to 2018-06-30-191,738USD91
2018-01-01 to 2018-03-31-188,567USD90
2017-01-01 to 2017-12-31-873,887USD365
2016-01-01 to 2016-12-31-2,068,619USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-12-312,202,713USD365
2018-01-01 to 2018-12-31-275,536USD365
2017-01-01 to 2017-12-31-314,005USD365
2016-01-01 to 2016-12-31-465,957USD366

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2019-01-01 to 2019-12-311,518,806USD365
2019-07-01 to 2019-09-30370USD92
2019-04-01 to 2019-06-301,507,590USD91
2019-01-01 to 2019-03-3110,847USD90
2018-01-01 to 2018-12-3144,300USD365
2018-07-01 to 2018-09-3011,178USD92
2018-04-01 to 2018-06-3010,847USD91
2018-01-01 to 2018-03-3111,427USD90
2017-01-01 to 2017-12-3144,951USD365
2016-01-01 to 2016-12-3143,512USD366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-12-3192,940USD365
2018-01-01 to 2018-12-31232,060USD365
2017-01-01 to 2017-12-31175,000USD365
2016-01-01 to 2016-12-3190,000USD366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2017-01-01 to 2017-12-31141,297USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-12-31-29,380,268USD
At 2019-09-30-29,229,751USD
At 2019-06-30-29,993,356USD
At 2019-03-31-31,117,854USD
At 2018-12-31-30,940,974USD
At 2018-09-30-30,728,459USD
At 2018-06-30-30,525,804USD
At 2018-03-31-30,334,066USD
At 2017-12-31-30,145,500USD
At 2016-12-31-29,271,613USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2019-01-01 to 2019-12-31388,646,386shares365
2018-01-01 to 2018-12-31271,718,989shares365
2017-01-01 to 2017-12-31271,718,989shares365
2016-01-01 to 2016-12-31271,718,989shares366

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2019-01-01 to 2019-12-31462,670,108shares365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2019-01-01 to 2019-12-310USD/shares365
2018-01-01 to 2018-12-310USD/shares365
2017-01-01 to 2017-12-310USD/shares365
2016-01-01 to 2016-12-310USD/shares366

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2019-01-01 to 2019-12-310USD/shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2019-01-01 to 2019-12-310USD365
2018-01-01 to 2018-12-310USD365
2017-01-01 to 2017-12-310USD365
2016-01-01 to 2016-12-310USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-3178,453USD365
2019-07-01 to 2019-09-30-227,964USD92
2019-04-01 to 2019-06-30614,299USD91
2019-01-01 to 2019-03-31-166,879USD90
2018-01-01 to 2018-12-31-769,620USD365
2018-07-01 to 2018-09-30-196,512USD92
2018-04-01 to 2018-06-30-185,738USD91
2018-01-01 to 2018-03-31-184,067USD90
2017-01-01 to 2017-12-31-859,600USD365
2016-01-01 to 2016-12-31-954,145USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-12-312,312,516USD
At 2019-09-302,540,992USD
At 2019-06-302,669,018USD
At 2019-03-3127,282USD
At 2018-12-3167USD
At 2018-09-304,539USD
At 2018-06-3021,658USD
At 2018-03-3196,766USD
At 2017-12-3143,543USD
At 2016-12-31195,625USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-01-01 to 2019-12-3137,333USD365
2019-07-01 to 2019-09-308,667USD92
2019-04-01 to 2019-06-308,667USD91
2019-01-01 to 2019-03-3110,000USD90
2018-01-01 to 2018-12-3125,854USD365
2018-07-01 to 2018-09-306,144USD92
2018-04-01 to 2018-06-306,000USD91
2018-01-01 to 2018-03-314,500USD90
2017-01-01 to 2017-12-311,210USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-12-312,783,023USD
At 2019-09-301,310,565USD
At 2019-06-30708,013USD
At 2019-03-31744,765USD
At 2018-12-311,146,723USD
At 2018-09-30667,001USD
At 2018-06-30626,127USD
At 2018-03-31586,598USD
At 2017-12-31551,383USD
At 2016-12-31289,848USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-12-3121,483USD
At 2019-09-3076,193USD
At 2019-06-3073,638USD
At 2019-03-31148,759USD
At 2018-12-31148,208USD
At 2018-09-30151,190USD
At 2018-06-30143,719USD
At 2018-03-31144,823USD
At 2017-12-31152,648USD
At 2016-12-3139,823USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2019-06-3021,548USD
At 2019-03-3187,227USD
At 2018-12-31152,908USD
At 2018-09-30218,588USD
At 2018-06-30284,267USD
At 2018-03-31349,947USD
At 2017-12-31415,627USD
At 2016-12-31678,346USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-01-01 to 2019-12-311,440,353USD365
2019-07-01 to 2019-09-30228,334USD92
2019-04-01 to 2019-06-30893,291USD91
2019-01-01 to 2019-03-31177,726USD90
2018-01-01 to 2018-12-31813,920USD365
2018-07-01 to 2018-09-30207,690USD92
2018-04-01 to 2018-06-30196,585USD91
2018-01-01 to 2018-03-31195,494USD90
2017-01-01 to 2017-12-31904,551USD365
2016-01-01 to 2016-12-31997,657USD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-01-01 to 2019-12-310USD365
2018-01-01 to 2018-12-310USD365
2017-01-01 to 2017-12-310USD365
2016-01-01 to 2016-12-3127,000USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-06-30268,718,989shares
At 2019-03-31268,718,989shares
At 2018-12-31268,718,989shares
At 2018-09-30268,718,989shares
At 2018-06-30268,718,989shares
At 2018-03-31268,718,989shares
At 2017-12-31268,718,989shares
At 2016-12-31268,718,989shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2019-12-312,295,720USD
At 2018-12-3167USD
At 2017-12-3143,543USD
At 2016-12-3141,251USD
At 2015-12-31417,208USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2019-03-317,231USD
At 2018-12-3118,077USD
At 2018-09-3028,924USD
At 2018-06-3039,771USD
At 2018-03-3143,388USD
At 2017-12-3143,388USD
At 2016-12-3143,388USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2019-01-01 to 2019-12-311,560,706USD365
2019-07-01 to 2019-09-30-236,395USD92
2019-04-01 to 2019-06-302,124,498USD91
2019-01-01 to 2019-03-31-176,879USD90
2018-01-01 to 2018-12-31-795,474USD365
2018-07-01 to 2018-09-30-202,656USD92
2018-04-01 to 2018-06-30-191,738USD91
2018-01-01 to 2018-03-31-188,567USD90
2017-01-01 to 2017-12-31-873,887USD365
2016-01-01 to 2016-12-31-2,068,619USD366

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2019-01-01 to 2019-12-311,482,253USD365
2019-07-01 to 2019-09-30-8,431USD92
2019-04-01 to 2019-06-301,510,199USD91
2019-01-01 to 2019-03-31-10,000USD90
2018-01-01 to 2018-12-31-25,854USD365
2018-07-01 to 2018-09-30-6,144USD92
2018-04-01 to 2018-06-30-6,000USD91
2018-01-01 to 2018-03-31-4,500USD90
2017-01-01 to 2017-12-31-14,287USD365
2016-01-01 to 2016-12-31-1,114,474USD366

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-01-01 to 2016-12-3190,000USD366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-126,725USD365
2018-01-01 to 2018-12-31-4,440USD365
2017-01-01 to 2017-12-31112,825USD365
2016-01-01 to 2016-12-3171,933USD366

Inspect the source

Entity
HEALTH DISCOVERY CORPORATION / CIK 0001141788
Captured
SEC response SHA-256
0d6fed061cdbc8ee974d84a3c55093843e6d411f7efb969a0fb9254c76a2e9fa

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001141788.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))